title: Preventing cardiovascular events with empagliflozin: at what cost?
authors.affiliation: LSE Health, Department of Social Policy, London School of Economics and Political Science, London WC2A 2AE, UK. Electronic address: h.naci@lse.ac.uk.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Naci
authors.affiliation: Prevention Research Center, Centers for Health Policy, Primary Care, and Outcomes Research, Center on Poverty and Inequality, and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Basu
authors.affiliation: Division of Medicine, University College London, London, UK.
authors.forename: John S
authors.initials: JS
authors.lastname: Yudkin
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents